Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving)
study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study.
The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of
survival in subjects with advanced non-small cell lung cancer who failed the first treatment.